DPA Omega-3: What It Is and How It Differs from EPA and DHA

Creator: Superpower
Published: 2026-04-03

Understand what your organ health supplements results really mean

See your biomarkers in context with a comprehensive panel.

CLIA-certified labs
HIPAA compliant
Personalized health protocol

Quick answer: DPA (docosapentaenoic acid) is the third major marine omega-3 fatty acid, found alongside EPA and DHA in fatty fish and fish oil. It is present in modest amounts in most omega-3 supplements and has been studied for roles in inflammation, platelet function, and conversion to other fatty acids. DPA is less researched than EPA or DHA but shares some of their biological activities and may act as a reservoir that the body converts to both.

What is DPA, and why does it matter?

When most people think about omega-3 fatty acids, they think about EPA and DHA. These two get the most attention in research, the most space on supplement labels, and the most discussion in clinical guidelines. But there is a third marine omega-3 that sits quietly between them in the metabolic pathway: docosapentaenoic acid, or DPA.

DPA (specifically n-3 DPA, also written as 22:5n-3) is present in the same foods that provide EPA and DHA — fatty fish, fish oil, krill oil, and some algal oils. It tends to appear in smaller concentrations than its better-studied counterparts, which is partly why it has received less research attention. That is beginning to change. Studies have started examining DPA's independent biological activities, and its role as a metabolic intermediate between EPA and DHA is becoming better understood.

Understanding DPA matters for anyone who reads omega-3 labels, follows fatty acid research, or is trying to interpret the growing body of work on omega-3 status and cardiovascular health.

The three marine omega-3s: EPA, DPA, and DHA

EPA (eicosapentaenoic acid, 20:5n-3)

EPA is a 20-carbon omega-3 fatty acid that serves as a direct precursor to a class of anti-inflammatory signaling molecules called eicosanoids, including prostaglandins, thromboxanes, and leukotrienes of the 3-series. These tend to be less pro-inflammatory than the equivalent molecules derived from arachidonic acid (an omega-6 fatty acid). EPA is also involved in platelet aggregation, vascular tone, and triglyceride regulation. It is the omega-3 most directly implicated in the cardiovascular benefits observed in high-dose fish oil trials like REDUCE-IT.

DHA (docosahexaenoic acid, 22:6n-3)

DHA is a 22-carbon omega-3 that accumulates preferentially in neural tissue and the retina. It is a structural component of cell membranes, particularly in the brain and eyes, where it influences membrane fluidity and receptor function. DHA is the dominant omega-3 in breast milk and is essential for fetal brain development. It also contributes to triglyceride lowering and anti-inflammatory signaling, though through different mechanisms than EPA.

DPA (docosapentaenoic acid, 22:5n-3)

DPA sits between EPA and DHA in carbon chain length and in the metabolic pathway. EPA is elongated to form DPA, which can then be further desaturated to form DHA. This places DPA in a bridging position: it is downstream of EPA and upstream of DHA. DPA also retrogrades to EPA when needed, meaning it may function as a circulating reserve of both parent fatty acids. Research published in the European Journal of Nutrition has shown that DPA supplementation raises plasma EPA concentrations, consistent with this bidirectional conversion capacity.

Where DPA is found

Fatty fish and marine sources

DPA is present in the same marine foods that supply EPA and DHA. Salmon, mackerel, sardines, herring, and tuna all contain measurable DPA, though in lower concentrations than EPA or DHA. Most analyses find DPA at roughly 10–20% of the EPA content in a given fish or fish oil product. Seal oil is an unusually rich DPA source, containing a higher DPA-to-EPA ratio than most fish oils, which has made it useful in research settings.

Fish oil and krill oil supplements

Standard fish oil capsules typically contain a mixture of EPA, DHA, and DPA. Because DPA concentrations are lower in raw fish oil and not typically highlighted in marketing, most supplement labels show only EPA and DHA totals. Consumers who look for DPA specifically will generally need to review certificates of analysis or contact manufacturers for detailed fatty acid profiles.

Red meat and dairy

DPA is also present in ruminant animal products — beef, lamb, and dairy. These provide the n-3 form of DPA (22:5n-3), the same metabolically active form found in marine sources. This is distinct from ALA (alpha-linolenic acid), the plant-derived omega-3 found in flaxseed and walnuts, which must undergo a separate, inefficient conversion pathway. Ruminant DPA is bioavailable and contributes meaningfully to DPA status in populations that consume red meat.

What DPA does in the body

Metabolic conversion to EPA and DHA

The most established function of DPA is as a metabolic intermediate. When the body requires EPA or DHA, DPA serves as a reserve substrate. Research suggests this conversion is physiologically significant — supplemental DPA raises circulating EPA levels, and the body preferentially incorporates DPA into membrane phospholipids from which it can be mobilized. This buffering function may be important during periods of low dietary omega-3 intake.

Platelet aggregation and thrombosis

DPA has been studied for effects on platelet function, which is relevant to cardiovascular health. In vitro studies have found that DPA inhibits platelet aggregation, a mechanism shared with EPA and DHA. Some research has suggested DPA may have comparable or greater antiplatelet activity than EPA on a molar basis, though most of this work has been conducted in cell or animal models. Human intervention data specific to DPA are limited.

Inflammation and lipid mediators

DPA gives rise to specialized pro-resolving mediators (SPMs) including a class called protectins and resolvins. SPMs are bioactive lipids that actively promote the resolution of inflammation rather than simply suppressing inflammatory initiation. Research from Charles Serhan's laboratory at Harvard has identified DPA-derived resolvins (RvDn-6 DPA series) that exhibit potent anti-inflammatory activity in preclinical models. Whether these translate to clinically meaningful effects in humans requires further investigation.

Vascular and endothelial function

DPA has been associated with effects on endothelial cell function, including promotion of endothelial cell migration and repair. Some observational studies have found inverse associations between plasma DPA and cardiovascular events, though distinguishing DPA's independent contribution from that of EPA and DHA in habitual fish consumers is methodologically difficult, as these fatty acids co-occur in the same foods and tend to be correlated in plasma.

Test 150+ biomarkers

Two blood draws. A full picture of your health, explained in plain language.

Book your test

Test 150+ biomarkers

Two blood draws. A full picture of your health, explained in plain language.

Book your test

DPA levels in the body and how they are measured

DPA status can be assessed through fatty acid profiling of plasma or red blood cell membranes. Red blood cell fatty acid analysis is generally preferred for assessing longer-term status, as red cell membranes reflect approximately three months of intake (similar to the logic behind HbA1c for blood sugar). Plasma fatty acid levels reflect more recent dietary intake.

These tests are not part of standard clinical blood panels. They are available through specialty laboratory testing and are most commonly ordered in research contexts or by clinicians evaluating omega-3 status comprehensively. Interpretation requires context: DPA values should be assessed alongside EPA and DHA rather than in isolation, and results are typically expressed as a percentage of total fatty acids rather than an absolute concentration.

For individuals interested in understanding their omega-3 status more broadly, a comprehensive metabolic panel can provide relevant context on cardiovascular and inflammatory markers. Superpower's Baseline Blood Panel includes lipids and inflammatory markers that complement fatty acid testing.

Should you look for DPA in your omega-3 supplement?

The practical guidance here is nuanced. DPA is present in most fish oil and krill oil products, even when not listed prominently. If you are consuming a high-quality fish oil that specifies EPA and DHA content, DPA is likely present as well.

Whether to specifically seek out high-DPA products — such as seal oil or specialty supplements marketed around DPA content — depends on your goals. The strongest clinical evidence for omega-3 supplementation remains concentrated around EPA and DHA. DPA's independent clinical evidence is more limited, though its biological activity and metabolic role suggest it is not inert. The broader pattern of consuming adequate total marine omega-3s from food and supplementation is more important than optimizing for any single fatty acid within the omega-3 family.

Which biomarkers are worth tracking alongside omega-3 intake?

Because omega-3 fatty acids are primarily studied in the context of cardiovascular and inflammatory health, the following biomarkers provide meaningful context for evaluating your omega-3 status and overall risk profile:

Triglycerides — High-dose omega-3s are among the most effective dietary interventions for lowering triglycerides
hs-CRP — systemic inflammation; EPA and DHA are associated with modest reductions
ApoB — Most accurate measure of atherogenic particle burden; relevant to cardiovascular risk assessment
HDL cholesterol — Omega-3s may modestly raise HDL in some individuals

This article is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before making changes to your health routine or supplement regimen.

Frequently Asked Questions

DPA (docosapentaenoic acid, 22:5n-3) is a 22-carbon marine omega-3 that sits metabolically between EPA (20:5n-3) and DHA (22:6n-3). EPA is elongated to form DPA, which can be further desaturated to DHA, placing DPA in a bridging position in the fatty acid pathway. Unlike EPA and DHA, DPA is found in lower concentrations in most marine foods and fish oils and has received comparatively less clinical research attention, though its independent biological activities are increasingly studied.

Yes. Because DPA can be retroconverted to EPA enzymatically, supplemental DPA has been shown to raise plasma EPA concentrations — research published in the European Journal of Nutrition confirmed this bidirectional conversion. DPA is also preferentially incorporated into membrane phospholipids from which it can be mobilized as a substrate for EPA or DHA synthesis. This buffering function may be important during periods of low dietary omega-3 intake.

DPA is typically present at lower concentrations than EPA or DHA in fish oil. A standard 1g fish oil capsule providing 180mg EPA and 120mg DHA might contain roughly 20–50mg DPA, though this varies considerably by product and source. Seal oil is an unusually rich DPA source, containing a notably higher DPA-to-EPA ratio than most fish oils, which has made it useful in DPA-specific research settings.

DPA gives rise to specialized pro-resolving mediators (SPMs) — including a class called protectins and resolvins — that actively promote the resolution of inflammation rather than simply suppressing its initiation. Research from Harvard has identified DPA-derived resolvins that exhibit potent anti-inflammatory activity in preclinical models. DPA also inhibits platelet aggregation in in vitro studies, an effect shared with EPA and DHA, though human clinical data specific to DPA remain limited.

Plant sources do not provide meaningful amounts of n-3 DPA directly. ALA from flaxseed, chia, and walnuts can theoretically be converted to EPA and then DPA, but this conversion is highly inefficient in humans. DPA from ruminant meat and dairy — beef, lamb, and dairy products — is bioavailable and in the same metabolically active n-3 form as marine DPA. Algal oils primarily provide DHA with varying EPA and little DPA.

DPA status can be assessed through fatty acid profiling of plasma or red blood cell membranes. Red blood cell fatty acid analysis is generally preferred for assessing longer-term status, as red cell membranes reflect approximately three months of intake — similar to the logic behind HbA1c for blood sugar monitoring. These tests are not part of standard clinical blood panels and are most commonly ordered in research contexts or by clinicians evaluating omega-3 status comprehensively.

DPA is rarely listed prominently on fish oil supplement labels. Because DPA concentrations are lower than EPA or DHA in raw fish oil and not typically highlighted in marketing, most supplement labels show only EPA and DHA totals. Consumers looking for DPA content specifically will generally need to review a product's certificate of analysis or contact the manufacturer for a detailed fatty acid profile rather than relying on the front label.

The strongest clinical evidence for omega-3 supplementation centers on EPA and DHA, and DPA's independent clinical data are more limited. Since DPA is present in most fish oils even when not labeled, prioritizing a high-quality fish oil with well-characterized EPA and DHA content and third-party testing for oxidation and contaminants is generally a more practical starting point than optimizing specifically for DPA. The broader pattern of adequate total marine omega-3 intake matters more than maximizing any single fatty acid.